

Excellent peri-implant tissues with Xeal™ and TiUltra™ surfaces for All-on-4® treatment concept

Clinical relevance

100% cumulative survival rate

No implant and no prosthetic failure after up to 3-year follow-up

Excellent bone response

from implant insertion to 1 year

Healthy soft tissue


No biological complications, and low modified plaque and bleeding indices



All-on-4 concept using TiUltra surface implants and Multi-unit Xeal abutments: Report on the outcomes between 6 to 36 months. Ana Ferro, Miguel De Araújo Nobre. Presented at the The European Association for Osseointegration (EAO) meeting September 28-30, 2023, Berlin, Germany

The results

- 100% implant survival and prosthetic success after up to 3-year follow-up.
- Low marginal bone remodeling of -0.39 mm from implant insertion to 1-year follow-up (n=35).
- Low modified plaque and bleeding indices of 1 for all patients at the last follow-up.
- No biological complications.
- Only minor mechanical complications occurred, in 9 of 43 patients. These were resolved by repair of the prosthesis in the laboratory, retightening the abutments, and occlusion adjustment.



Study design

Retrospective, single-center clinical study



Fully edentulous



43 patients



172 NobelParallel CC TiUltra and Multi-unit Abutments Xeal



43 fixed full-arch prostheses



Up to 3-year follow-up

Sample clinical case from the study




Image courtesy of Dr. Ana Ferro, Portugal

A/E A 46-year-old female patient, smoker, with failing dentition and a high smile line was treated according to the All-on-4® treatment concept with four NobelParallel CC TiUltra implants and Multi-unit Abutments Xeal. **F** Patient received all-acrylic bridge 2 hours after surgery. **G/H** Analysis of OPG at 1 year, and peri-apical radiographs at 3 years show excellent peri-implant bone stability. **I** Patient smile

Authors' conclusion

“Full-arch rehabilitations *ad modum* All-on-4® treatment concept using gradually anodized dental implants [TiUltra] and anodized abutments [Xeal] demonstrate low marginal bone loss and healthy soft tissue response during a 23-month follow-up.”

More to explore



Science First –
All-on-4® treatment



Blog-Interview with
Tomas Albrektsson
and Ana Ferro



Nobelbiocare.com/all-on-4

GMT 86815 GB 2310 © Nobel Biocare Services AG, 2023. All rights reserved. Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Product images are not necessarily to scale. All product images are for illustration purposes only and may not be an exact representation of the product. Disclaimer: Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment and availability. See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions

**Nobel
Biocare™**